Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes

ClinicalTrials.gov ID: NCT01338870

Public ClinicalTrials.gov record NCT01338870. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 8:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 12-week, Phase 2, Randomized, Double-blind, Placebo Controlled, Dose-ranging, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Pf-04991532 and Once Daily Sitagliptin in Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin

Study identification

NCT ID
NCT01338870
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Pfizer
Industry
Enrollment
301 participants

Conditions and interventions

Interventions

  • 150 mg PF-04991532 Drug
  • 25 mg PF-04991532 Drug
  • 300 mg PF-04991532 Drug
  • 75 mg PF-04991532 Drug
  • Placebo Drug
  • Sitagliptin 100 mg Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2011
Primary completion
Feb 29, 2012
Completion
Feb 29, 2012
Last update posted
Apr 22, 2013

2011 – 2012

United States locations

U.S. sites
25
U.S. states
19
U.S. cities
25
Facility City State ZIP Site status
Pfizer Investigational Site Little Rock Arkansas 72205
Pfizer Investigational Site Roseville California 95661
Pfizer Investigational Site Denver Colorado 80209
Pfizer Investigational Site Coral Gables Florida 33134
Pfizer Investigational Site Ocala Florida 34471
Pfizer Investigational Site Honolulu Hawaii 96814
Pfizer Investigational Site Indianapolis Indiana 46260
Pfizer Investigational Site Augusta Kansas 67010
Pfizer Investigational Site Overland Park Kansas 66215
Pfizer Investigational Site Wichita Kansas 67207
Pfizer Investigational Site Lexington Kentucky 40504
Pfizer Investigational Site Lake Charles Louisiana 70601
Pfizer Investigational Site Auburn Maine 04210
Pfizer Investigational Site Brooklyn Center Minnesota 55430
Pfizer Investigational Site Las Vegas Nevada 89101
Pfizer Investigational Site Trenton New Jersey 08611
Pfizer Investigational Site Charlotte North Carolina 28277
Pfizer Investigational Site Fargo North Dakota 58103
Pfizer Investigational Site Cincinnati Ohio 45245
Pfizer Investigational Site Lansdale Pennsylvania 19446
Pfizer Investigational Site Dallas Texas 75246
Pfizer Investigational Site Katy Texas 77450
Pfizer Investigational Site San Antonio Texas 78229
Pfizer Investigational Site Norfolk Virginia 23502
Pfizer Investigational Site Richmond Virginia 23294

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01338870, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 22, 2013 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01338870 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →